Search results: Sage Journals

Open accessResearch articleFirst published August, 2024

Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial

Sheng Li, Xiaoyou Li, Qianni Zhu [...]

Cancer Control

Open accessResearch articleFirst published 2020

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study,a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

Daniela Bianconi, Merima Herac, Florian Posch [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

Conventional Therapy Combined With Quxie Capsule Modulating Gut Microbiome in Metastatic Colorectal Cancer Patients With the Third or Above Line Setting: Result From an Investigator-Initiated,Open-Label,Single-Arm,Phase II Study

Zhien Gu, Lei Wang, Jiawei Zhai MA [...]

Integrative Cancer Therapies

Restricted accessResearch articleFirst published July, 2011

Estimating the Unknown Parameters of the Natural History of Metachronous Colorectal Cancer Using Discrete-Event Simulation

Fatih Safa Erenay, Oguzhan Alagoz, Ritesh Banerjee [...]

Medical Decision Making

Free accessReview articleFirst published July, 2016

Current targeted therapies in the treatment of advanced colorectal cancer: a review

Andrew Moriarity, Jacintha O’Sullivan, John Kennedy [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published May, 2025

Type IV collagen,carcinoembryonic antigen,osteopontin,and hepatocyte growth factor as biomarkers for liver metastatic colorectal cancer

Moa Lindgren, Ingrid Ljuslinder, Pär Jonsson [...]

The International Journal of Biological Markers

Open accessReview articleFirst published 2022

Encorafenib plus cetuximab for the treatment of BRAF-V600E -mutated metastatic colorectal cancer

Javier Ros, Nadia Saoudi, Iosune Baraibar [...]

Therapeutic Advances in Gastroenterology

Restricted accessResearch articleFirst published April, 2025

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten [...]

Journal of Oncology Pharmacy Practice

Free accessOtherFirst published May, 2010

Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer

Stefan Peinert, Wilfried Grothe, Alexander Stein [...]

Therapeutic Advances in Medical Oncology

Free accessReview articleFirst published February, 2017

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Rachel Riechelmann, Axel Grothey

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published August, 2024

Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial

Sheng Li, Xiaoyou Li, Qianni Zhu [...]

Cancer Control

Open accessResearch articleFirst published 2020

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study,a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC

Daniela Bianconi, Merima Herac, Florian Posch [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2024

Conventional Therapy Combined With Quxie Capsule Modulating Gut Microbiome in Metastatic Colorectal Cancer Patients With the Third or Above Line Setting: Result From an Investigator-Initiated,Open-Label,Single-Arm,Phase II Study

Zhien Gu, Lei Wang, Jiawei Zhai MA [...]

Integrative Cancer Therapies

Restricted accessResearch articleFirst published July, 2011

Estimating the Unknown Parameters of the Natural History of Metachronous Colorectal Cancer Using Discrete-Event Simulation

Fatih Safa Erenay, Oguzhan Alagoz, Ritesh Banerjee [...]

Medical Decision Making

Free accessReview articleFirst published July, 2016

Current targeted therapies in the treatment of advanced colorectal cancer: a review

Andrew Moriarity, Jacintha O’Sullivan, John Kennedy [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published May, 2025

Type IV collagen,carcinoembryonic antigen,osteopontin,and hepatocyte growth factor as biomarkers for liver metastatic colorectal cancer

Moa Lindgren, Ingrid Ljuslinder, Pär Jonsson [...]

The International Journal of Biological Markers

Open accessReview articleFirst published 2022

Encorafenib plus cetuximab for the treatment of BRAF-V600E -mutated metastatic colorectal cancer

Javier Ros, Nadia Saoudi, Iosune Baraibar [...]

Therapeutic Advances in Gastroenterology

Restricted accessResearch articleFirst published April, 2025

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten [...]

Journal of Oncology Pharmacy Practice

Free accessOtherFirst published May, 2010

Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer

Stefan Peinert, Wilfried Grothe, Alexander Stein [...]

Therapeutic Advances in Medical Oncology

Free accessReview articleFirst published February, 2017

Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies

Rachel Riechelmann, Axel Grothey

Therapeutic Advances in Medical Oncology